News
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening ...
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...
15h
GlobalData on MSNModerna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump
Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that ...
Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...
Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...
The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...
Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...
Moderna has announced that it plans to cut down 10% of its workforce by the end of the year. CEO Stephane Bancel said in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results